title: Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.
abstract: Since the cholinergic hypothesis of memory dysfunction was first reported, extensive research efforts have focused on elucidating the mechanisms by which this intricate system contributes to the regulation of processes such as learning, memory, and higher executive function. Several cholinergic therapeutic targets for the treatment of cognitive deficits, psychotic symptoms, and the underlying pathophysiology of neurodegenerative disorders, such as Alzheimer's disease and schizophrenia, have since emerged. Clinically approved drugs now exist for some of these targets; however, they all may be considered suboptimal therapeutics in that they produce undesirable off-target activity leading to side effects, fail to address the wide variety of symptoms and underlying pathophysiology that characterize these disorders, and/or afford little to no therapeutic effect in subsets of patient populations. A promising target for which there are presently no approved therapies is the M1 muscarinic acetylcholine receptor (M1 mAChR). Despite avid investigation, development of agents that selectively activate this receptor via the orthosteric site has been hampered by the high sequence homology of the binding site between the five muscarinic receptor subtypes and the wide distribution of this receptor family in both the central nervous system (CNS) and the periphery. Hence, a plethora of ligands targeting less structurally conserved allosteric sites of the M1 mAChR have been investigated. This Review aims to explain the rationale behind allosterically targeting the M1 mAChR, comprehensively summarize and critically evaluate the M1 mAChR allosteric ligand literature to date, highlight the challenges inherent in allosteric ligand investigation that are impeding their clinical advancement, and discuss potential methods for resolving these issues.
authors: Medicinal Chemistry and Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.
authors: Briana J
authors: BJ
authors: Davie
authors: Arthur
authors: A
authors: Christopoulos
authors: Peter J
authors: PJ
authors: Scammells
mesh_terms: D000494:Allosteric Regulation / Q000187:drug effects / Q000502:physiology; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D003072:Cognition Disorders / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D055808:Drug Discovery; D006801:Humans; D008024:Ligands; D043643:Receptor, Muscarinic M1 / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D008024:Ligands; D043643:Receptor, Muscarinic M1
references: Am J Psychiatry. 2001 Jun;158(6):918-25
references: 11384900
references: ACS Med Chem Lett. 2010 Jun 08;1(6):244-8
references: 24900202
references: Bioorg Med Chem Lett. 2012 May 15;22(10):3467-72
references: 22507963
references: Bioorg Med Chem Lett. 2011 Mar 15;21(6):1710-5
references: 21324684
references: Mol Pharmacol. 2007 Dec;72(6):1484-96
references: 17848601
references: Schizophr Res. 2000 May 5;42(3):249-59
references: 10785583
references: Life Sci. 2001 Apr 27;68(22-23):2517-24
references: 11392621
references: Br J Pharmacol. 2012 Mar;165(6):1659-1669
references: 22023017
references: Neuropharmacology. 2011 Jan;60(1):24-35
references: 20637785
references: Bioorg Med Chem Lett. 2012 Aug 1;22(15):5134-40
references: 22677319
references: Prog Brain Res. 2008;172:199-212
references: 18772034
references: J Neurosci. 2009 Nov 11;29(45):14271-86
references: 19906975
references: J Biol Chem. 2011 Feb 18;286(7):4978-90
references: 21118814
references: Expert Opin Ther Pat. 2012 Dec;22(12):1385-98
references: 23092292
references: Clin Ther. 2004 May;26(5):649-66
references: 15220010
references: Bioorg Med Chem Lett. 2008 Oct 15;18(20):5443-7
references: 18829311
references: Neuropharmacology. 2010 Feb;58(2):365-73
references: 19835892
references: Bioorg Med Chem Lett. 2010 Jan 15;20(2):657-61
references: 19962304
references: Bioorg Med Chem Lett. 2011 May 1;21(9):2769-72
references: 21055928
references: Neuron. 2006 Mar 2;49(5):671-82
references: 16504943
references: Bioorg Med Chem Lett. 2010 Apr 15;20(8):2533-7
references: 20303264
references: J Biol Chem. 1994 Feb 11;269(6):4092-7
references: 8307968
references: Nat Rev Drug Discov. 2013 Mar;12(3):205-16
references: 23411724
references: Bioorg Med Chem Lett. 2011 Nov 1;21(21):6451-5
references: 21930376
references: Mol Pharmacol. 2009 Mar;75(3):577-88
references: 19047481
references: Bioorg Med Chem Lett. 2008 Oct 15;18(20):5439-42
references: 18805692
references: Nat Rev Drug Discov. 2005 Nov;4(11):919-27
references: 16264435
references: Neuropharmacology. 2010 Jun;58(8):1206-14
references: 20206188
references: Bioorg Med Chem Lett. 2011 May 1;21(9):2697-701
references: 21194936
references: Bioorg Med Chem Lett. 2010 Jan 15;20(2):531-6
references: 20004574
references: Bioorg Med Chem Lett. 2013 Jan 1;23(1):223-7
references: 23200253
references: CNS Drug Rev. 2003 Summer;9(2):159-86
references: 12847557
references: Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83
references: 18678919
references: Nature. 2007 Nov 15;450(7168):383-7
references: 17952055
references: Arch Neurol. 1997 Apr;54(4):465-73
references: 9109749
references: Bioorg Med Chem Lett. 2010 Apr 15;20(8):2538-41
references: 20346667
references: Curr Med Chem. 2004 Feb;11(3):343-58
references: 14965236
references: Behav Brain Res. 2011 Sep 12;222(1):151-7
references: 21421012
references: Bioorg Med Chem Lett. 2010 Mar 15;20(6):1972-5
references: 20156687
references: ACS Med Chem Lett. 2012 Oct 13;3(12):1070-4
references: 24900430
references: Mol Pharmacol. 1999 Dec;56(6):1245-53
references: 10570052
references: Prog Neurobiol. 2012 Apr;97(1):1-13
references: 22387368
references: Behav Neurosci. 2008 Jun;122(3):570-5
references: 18513127
references: Science. 1982 Mar 5;215(4537):1237-9
references: 7058341
references: Trends Pharmacol Sci. 2006 Sep;27(9):475-81
references: 16889837
references: Trends Cogn Sci. 2012 Jan;16(1):35-42
references: 22178120
references: Neuropsychopharmacology. 2010 Mar;35(4):855-69
references: 19940843
references: Mol Biosyst. 2010 Aug;6(8):1345-54
references: 20582339
references: Mol Pharmacol. 2009 Feb;75(2):331-41
references: 19001633
references: Trends Biochem Sci. 2011 Dec;36(12):663-72
references: 21920759
references: Life Sci. 1997;60(13-14):1047-52
references: 9121346
references: Trends Pharmacol Sci. 2009 Mar;30(3):148-55
references: 19201489
references: Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5
references: 19717450
references: Neurodegener Dis. 2008;5(3-4):237-40
references: 18322400
references: Bioorg Med Chem Lett. 2010 Feb 15;20(4):1334-7
references: 20097564
references: J Med Chem. 2010 Sep 9;53(17):6386-97
references: 20684563
references: J Neurosci. 2008 Oct 8;28(41):10422-33
references: 18842902
references: Neuron. 2010 Dec 9;68(5):948-63
references: 21145007
references: Science. 2008 Nov 21;322(5905):1211-7
references: 18832607
references: Biochem Pharmacol. 1983 Aug 15;32(16):2375-83
references: 6311215
references: Br J Pharmacol. 1999 Apr;126(7):1620-4
references: 10323594
references: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13674-9
references: 14595031
references: Trends Pharmacol Sci. 2003 Jul;24(7):346-54
references: 12871667
references: Bioorg Med Chem Lett. 2010 Jun 15;20(12):3540-4
references: 20483611
references: Bioorg Med Chem Lett. 2006 Mar 1;16(5):1217-20
references: 16364641
references: J Neurosci. 2012 Jun 20;32(25):8532-44
references: 22723693
references: Ann Neurol. 1991 Mar;29(3):256-62
references: 2042942
references: Mol Pharmacol. 2010 Jul;78(1):94-104
references: 20413650
references: Annu Rev Pharmacol Toxicol. 2004;44:423-50
references: 14744253
references: FASEB J. 2009 Feb;23(2):442-50
references: 18842964
references: Mol Psychiatry. 2007 Mar;12(3):232-46
references: 17146471
references: Science. 2000 Aug 4;289(5480):739-45
references: 10926528
references: Nature. 2012 Feb 22;482(7386):552-6
references: 22358844
references: Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11465-70
references: 9736760
references: Mol Pharmacol. 2012 Jan;81(1):41-52
references: 21989256
references: Arch Gen Psychiatry. 1992 Jul;49(7):538-44
references: 1352677
references: J Pharmacol Exp Ther. 2009 Dec;331(3):1086-95
references: 19767446
references: Mol Interv. 2009 Jun;9(3):125-35
references: 19592673
references: Proc Natl Acad Sci U S A. 1990 Aug;87(15):6003-6
references: 2116015
references: Eur J Pharmacol. 2009 Jan 28;603(1-3):147-9
references: 19111716
references: Mol Pharmacol. 2007 Aug;72(2):463-76
references: 17525129
references: Mol Pharmacol. 2006 Jan;69(1):236-46
references: 16207821
references: J Neurochem. 2012 Jan;120 Suppl 1:22-33
references: 22122190
references: ACS Chem Neurosci. 2010;1(2):104-121
references: 21961051
references: Neuropsychopharmacology. 2010 Mar;35(4):851-2
references: 20145632
references: Annu Rev Pharmacol Toxicol. 2007;47:1-51
references: 17009927
references: Science. 1982 Jul 30;217(4558):408-14
references: 7046051
references: Curr Drug Metab. 2006 Feb;7(2):183-203
references: 16472107
references: Biol Psychiatry. 2000 Sep 1;48(5):381-8
references: 10978721
references: Pharmacol Ther. 2008 Jul;119(1):33-43
references: 18558434
references: Ann N Y Acad Sci. 2000;920:321-7
references: 11193171
references: J Chem Neuroanat. 2010 Sep;40(1):63-70
references: 20347961
references: Br J Pharmacol. 2011 Apr;162(7):1659-70
references: 21198541
references: Mol Pharmacol. 2005 Dec;68(6):1506-9
references: 16183853
references: J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47
references: 10071091
references: ACS Chem Neurosci. 2012 Dec 19;3(12):1025-36
references: 23259038
references: Expert Opin Investig Drugs. 2000 Oct;9(10):2259-67
references: 11060805
references: Mol Pharmacol. 2000 Jul;58(1):194-207
references: 10860942
references: J Med Chem. 2000 Nov 16;43(23):4333-53
references: 11087557
references: Annu Rev Pharmacol Toxicol. 1990;30:633-73
references: 2188581
references: Am J Psychiatry. 2008 Aug;165(8):1033-9
references: 18593778
references: Mol Pharmacol. 2002 Dec;62(6):1492-505
references: 12435818
references: Br J Pharmacol. 2008 Jul;154(5):1104-15
references: 18454168
references: Bioorg Med Chem Lett. 2010 Jun 15;20(12):3545-9
references: 20483599
references: Br J Pharmacol. 1983 Feb;78(2):257-9
references: 6187403
references: Neurosci Lett. 2000 Jan 7;278(1-2):61-4
references: 10643801
references: Mol Pharmacol. 2006 Dec;70(6):1974-83
references: 16959945
references: Clin Ther. 2005 Nov;27(11):1725-51
references: 16368445
references: J Biol Chem. 2008 Oct 24;283(43):29312-21
references: 18723515
references: ACS Med Chem Lett. 2010 Jun 04;1(6):263-7
references: 24900206
references: Pharmacol Ther. 1993 Jun;58(3):319-79
references: 7504306
references: Mol Pharmacol. 1995 Aug;48(2):362-78
references: 7651370
references: Neurochem Res. 2003 Apr;28(3-4):437-42
references: 12675128
references: Eur J Pharmacol. 2012 Dec 15;697(1-3):73-80
references: 23085025
references: Ann N Y Acad Sci. 2000;920:315-20
references: 11193170
references: Mol Pharmacol. 2002 Jun;61(6):1297-302
references: 12021390
references: Bioorg Med Chem Lett. 2013 Jan 15;23(2):412-6
references: 23237839
references: Int J Neuropsychopharmacol. 2013 May;16(4):721-31
references: 22932339
references: Amyloid. 2003 Mar;10(1):1-6
references: 12762134
references: Psychopharmacology (Berl). 2013 Jan;225(1):21-30
references: 22825578
references: Mol Cell Endocrinol. 2011 Jan 15;331(2):170-8
references: 20708652
references: Trends Pharmacol Sci. 2013 Jan;34(1):59-66
references: 23177916
references: J Neurochem. 1995 Apr;64(4):1888-91
references: 7891119
references: ACS Chem Neurosci. 2012 Nov 21;3(11):884-95
references: 23173069
references: Lancet. 1976 Dec 25;2(8000):1403
references: 63862
references: Pharmacol Ther. 2003 May;98(2):197-220
references: 12725869
references: Bioorg Med Chem Lett. 2013 Mar 15;23(6):1860-4
references: 23416001
references: J Neurosci. 2001 Jul 15;21(14):5239-50
references: 11438599
references: J Biol Chem. 2012 Jan 2;287(1):650-659
references: 22086918
references: Nature. 2012 Jan 25;482(7386):547-51
references: 22278061
references: Neuropharmacology. 2013 Jan;64:13-26
references: 22796429
references: FASEB J. 2004 Sep;18(12):1410-2
references: 15231726
references: Nat Rev Drug Discov. 2002 Mar;1(3):198-210
references: 12120504
references: J Pharmacol Exp Ther. 2008 Nov;327(2):365-74
references: 18664591
references: Bioorg Med Chem Lett. 2010 Sep 15;20(18):5434-8
references: 20709550
references: J Neurosci. 2011 Dec 14;31(50):18464-78
references: 22171048
references: Neurobiol Aging. 2007 Sep;28(9):1381-7
references: 16828202
references: Pharmacol Ther. 2008 Feb;117(2):232-43
references: 18082893
references: J Pharmacol Exp Ther. 1997 Jul;282(1):278-85
references: 9223565
references: Prog Neurobiol. 2003 May;70(1):1-32
references: 12927332